Acute appendicitis NOS (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of uPA and especially the over-expression of PAI-1 seem to correlate to the progression of local inflammatory response in acute appendicitis.
|
19153874 |
2009 |
Acute Cerebrovascular Accidents
|
0.300 |
Biomarker
|
disease |
CTD_human |
Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke.
|
12742636 |
2003 |
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Acute Lung Injury
|
0.210 |
Therapeutic
|
disease |
RGD |
Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats.
|
23324284 |
2013 |
Acute Lung Injury
|
0.210 |
GeneticVariation
|
disease |
LHGDN |
Association between urokinase haplotypes and outcome from infection-associated acute lung injury.
|
17994220 |
2008 |
Acute Lung Injury
|
0.210 |
Biomarker
|
disease |
RGD |
[Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model].
|
21473829 |
2011 |
Acute myocardial infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study established that uPA gene therapy effectively induces functionally significant angiogenesis in models of acute MI and hind limb ischemia.
|
17653104 |
2007 |
Acute myocardial infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction.
|
30889909 |
2019 |
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
We examined mRNA expression of the urokinase-type plasminogen activator (uPA), its receptor (uPAR), and the plasminogen activator inhibitor 1 (PAI-1) in a panel of adenocarcinomas of the pancreas (PC) and cancers of the papilla of Vater (CPV).
|
18376309 |
2008 |
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the role of the uPAR/uPA system in both the development and progression of pancreatic cancer in invasive ductal adenocarcinomas of the pancreas (PDA) and their premalignant precursors (PanIN lesions) in 50 patients with long-term clinical follow-up.
|
19435784 |
2009 |
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
LHGDN |
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
|
18376307 |
2008 |
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
BEFREE |
Using in situ hybridization to analyze the coexpression of laminin-5 and components of the plasminogen activation system, we found that the histological distribution of laminin-5-positive budding cancer cells at the invasion front in colon adenocarcinomas was identical to that of the receptor for urokinase-type plasminogen activator.
|
7664291 |
1995 |
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
LHGDN |
We have studied the expression of urokinase-type plasminogen activator (uPA) mRNA, uPA receptor (uPAR) mRNA and immunoreactivity, and type-1 plasminogen activator inhibitor (PAI-1) mRNA and immunoreactivity in 16 prostate adenocarcinomas and 9 benign prostate hyperplasias. uPA mRNA and uPAR mRNA expression were found in 9 and 8 of the adenocarcinomas, respectively, and in 7 and 6 of the benign hyperplasias, respectively.
|
15515049 |
2005 |
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
CTD_human |
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
|
10467400 |
1999 |
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
The inhibitory effects of amiloride on uPA gene expression reported in this paper may offer the prospect of developing new therapeutic approaches to the prevention of invasion and metastasis by adenocarcinomas.
|
7750207 |
1995 |
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
|
1850957 |
1991 |
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
We have studied the expression of urokinase-type plasminogen activator (uPA) mRNA, uPA receptor (uPAR) mRNA and immunoreactivity, and type-1 plasminogen activator inhibitor (PAI-1) mRNA and immunoreactivity in 16 prostate adenocarcinomas and 9 benign prostate hyperplasias. uPA mRNA and uPAR mRNA expression were found in 9 and 8 of the adenocarcinomas, respectively, and in 7 and 6 of the benign hyperplasias, respectively.
|
15515049 |
2005 |
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
BEFREE |
Finally, expression of miR-193a is inversely correlated with PLAU and K-Ras in human colon adenocarcinomas.
|
21670079 |
2011 |
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
The expressions of uPA and p38MAPK proteins were significantly higher in esophageal squamous cell carcinoma or adenocarcinoma than in normal esophageal mucosa tissue (both <i>P</i><0.0001).
|
30568465 |
2018 |
Adenocarcinoma of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
We first showed that active site-inhibited u-PA could displace endogenous u-PA from the surface of the human colon adenocarcinoma cell line HCT 116.
|
1648983 |
1991 |
Adenocarcinoma of pancreas
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
|
10467400 |
1999 |
Adenocarcinoma of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
The median and range of the ratios of uPA mRNA measures between tumor tissue and non-involved pancreatic tissue was 17.1 (1.4-653.6) for pancreatic adenocarcinoma (P < 0.001), 3.9 (0.7-7.7) for ampullary carcinoma (P = 0.055) and 1.9 (0.6-5.9) for mucinous cystadenoma tissue (P = 0.052). uPA low tumors were associated with an exuberant stromal reaction, whereas uPA high tumors showed little stromal response.
|
15683429 |
2005 |
Adenocarcinoma, Basal Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
|
10467400 |
1999 |
Adenocarcinoma, Oxyphilic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
|
10467400 |
1999 |
Adenocarcinoma, Tubular
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
|
10467400 |
1999 |